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Capsule 
Background: Tendon disease is characterised 
by extensive remodelling of the extracellular 
matrix. 
Results: Novel COMP cleavage fragments 
were identified in both an in vitro 
inflammatory model and natural disease. 
Conclusion: Inflammatory mediators drive 
distinct COMP fragmentation at different 
stages of tendon disease. 
 
Significance: Novel COMP neo-terminal 
fragments provide opportunities for 
developing markers for tendon injury. 
Abstract 
During inflammatory processes the 
extracellular matrix (ECM) is extensively 
remodelled and many of the constituent 
components are released as proteolytically 
cleaved fragments. These degradative 
processes are better documented for 
inflammatory joint diseases than tendinopathy 
even though the pathogenesis has many 
similarities. The aims of this study were to 
investigate the proteomic composition of  
 
injured tendons during early and late disease 
stages to identify disease-specific cleavage 
patterns of the ECM protein Cartilage 
oligomeric matrix protein (COMP). In addition 
to characterising fragments released in 
naturally occurring disease, we hypothesised 
that stimulation of tendon explants with pro-
inflammatory mediators in vitro would induce 
fragments of COMP analogous to natural 
disease. Therefore normal tendon explants 
were stimulated with IL-1β and PGE2 and their 
effects on the release of COMP and its 
cleavage patterns were characterised. Analyses 
of injured tendons identified an altered 
proteomic composition of the ECM at all 
stages post injury, showing protein fragments 
that were specific to disease stage. IL-1β 
enhanced the proteolytic cleavage and release 
of COMP from tendon explants, whilst PGE2 
had no catabolic effect.  Of the cleavage 
fragments identified in early stage tendon 
disease, 2 fragments were generated by an IL-
1 mediated mechanism. These fragments 
provide a platform for the development of neo-
epitope assays specific to injury stage for 
tendon disease. 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M113.511972The latest version is at 
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Introduction 
Tendons have an abundant extracellular matrix 
(ECM) and are significant causes of morbidity 
in athletic individuals (1,2). Repetitive 
mechanical loading during exercise and 
inflammation are driving factors in the 
aetiopathogenesis of injury (3-5). The horse 
presents an attractive large animal model for 
the study of the functionally equivalent human 
Achilles tendon due to the shared 
characteristics of aging phenotypes (6,7) and 
elastic energy storing function common to the 
weight-bearing tendons of both species (8,9). 
Exercise studies in mature horses have failed 
to show evidence of an adaptive response to 
loading and it is suggested that exercise 
instead drives degeneration, which precedes 
clinical injury in adult tendon (10,11).  This 
concept was supported by studies in the 
tensional regions of bovine digital flexor 
tendons where ECM turnover based on mRNA 
expression was shown to be low (12) and this 
has been further supported in recent studies in 
the horse where the remodelling rate of 
collagen was found to be negligible (half-life 
of 198 years) (13). Whilst initial studies of 
human Achilles tendons suggested continued 
remodelling in adult tendons based on 
microdialysis (14,15), recent data has 
confirmed that the central area of this tendon 
also has minimal turn-over rate in the adult 
(16), confirming the horse as a highly relevant 
model for human tendon disease (17).  In 
contrast, the non-collagenous components of 
tendon appear to be more rapidly turned over 
and therefore are likely to be influenced by the 
degradative processes responsible for the 
hypothesised changes that occur prior to 
clinical injury (11,18). 
Equine tendon repair processes are frequently 
clinically classified into three phases in 
naturally occurring injury; the acute phase 
occurs immediately after the initial trauma 
lasting only a few days, followed by sub-acute 
(3-6 weeks) and chronic injury phases (>3 
months after injury) (19).  This healing 
response induces profound changes in the 
composition of the tendon ECM (20-22) 
associated with the formation of scar tissue 
which is believed to be responsible for poor 
functional outcome in both species (23).  
COMP is a pentameric glycoprotein belonging 
to the thrombospondin family (24) that is 
found in many mechanically loaded tissues 
including tendon (25). Its functions are 
thought to include stabilizing the collagen 
fiber network and catalyzing fibrillogenesis 
(26,27), and in assembly, organization and 
maintenance of the ECM (28). These roles 
would explain its strong relationship to tendon 
mechanical properties in equine tendons (29).  
COMP levels and fragments are elevated in 
joint disease and reported in the synovial 
fluids and serum of patients with rheumatoid 
arthritis and osteoarthritis (26,30). Equids with 
intrathecal digital flexor tendon tears also 
show elevated COMP levels in tendon sheath 
fluids (31,32). COMP degradation is mediated 
in part by MMPs (33), although MMP 
independent pathways involving the 
aggrecanase ADAMTS-4 (28) also occur.  
A growing body of recent evidence from 
studying tendon tissues from humans (34,35), 
equids (3,36), rodents (37) and in vitro models 
(38) support the role of inflammation in 
tendinopathy, implicating pro-inflammatory 
mediators such as IL-1 and PGE2 in disease 
development and progression. The role of 
inflammatory cytokines in non-collagenous 
matrix breakdown has been investigated 
extensively in cartilage in vitro and in vivo as 
typified by loss of COMP and proteoglycans 
(28,39-42). While tendon and tendon 
fibroblasts produce and respond to cytokine 
stimulation (43), their role in the specific 
cleavage of ECM proteins is less well 
documented (28,39,40). The ability to detect 
specific proteolytic cleavage sites is necessary 
to understand tendon ECM degradative 
mechanisms that are disease-stage specific for 
both targeted therapeutic interventions as well 
as identifying neo-terminal peptide fragments 
for developing markers for sub-clinical disease 
for preventative strategies (41). Equine 
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tendons present a more readily attainable 
source than the human counterpart, permitting 
targeted investigation of disease through each 
injury phase as well as normal (uninjured) 
tendons of a wide age range.  The aim of this 
study was to identify COMP fragments 
generated at different stages of tendon disease 
and to relate these to those induced 
specifically by IL-1β and PGE2 in vitro. This 
is the first comprehensive analysis of tendon 
ECM degradation in acute and chronic disease 
and we identify novel COMP fragments in 
natural disease that are produced by an IL-1 
driven mechanism.  
Experimental procedures 
Collection of equine tendons 
Equine forelimbs from Thoroughbred or 
Thoroughbred cross breed horses aged 
between 2-20 years were obtained from an 
abattoir or local equine referral hospital with 
known history of injury and the tensile (mid-
metacarpal) region of the superficial digital 
flexor tendon (SDFT) harvested within 4 h of 
death. Tendons were grouped as sub-acutely 
injured (3-6 weeks post injury, n=6, mean age 
9 ± 5 years) or chronically injured (>3 months 
post injury, n=9, mean age 13 ± 4 years), as 
described before (3). Tendon injuries were 
aged based on historical information obtained 
from either the owner or referring veterinary 
surgeon prior to euthanasia of the horse. 
Tendons were classified as normal based on 
their macroscopic post mortem appearance, 
which included lack of visible signs of 
swelling of the tendon body, and a consistent 
pattern of fascicles on haematoxylin and eosin 
stained sections (n=19, mean age 8 ± 5 years). 
Preparation of tendon explants for 
tissue culture 
Macroscopically normal tendons were used for 
in vitro experiments and derived from horses 
(n=10) between 7-14 years of age (mean 10 ± 
3 years). SDFTs were aseptically dissected 
from the limb and after removal of the 
paratenon, tendon explants were cut in a tissue 
culture flow hood using 3 parallel sterile 
microtome blades (Surgipath, UK) inserted 
into a custom designed cutting template to 
create 2 mm x 2 mm x 37 mm pieces along the 
longitudinal axis of the tendon (6). Two 
explants per well were cultured in serum 
depleted DMEM (3 ml per well) containing 
5% penicillin and streptomycin (Invitrogen, 
UK) in tissue culture 6 well plates (VWR, UK) 
at 37 °C in humidified atmosphere (5% CO2 
and air). This method of preparing the explant 
tissue consistently produced average wet 
weights of 300 mg (±30 mg). 
To assess the effects of pro-inflammatory 
mediators on release of tendon matrix 
components, explants were stimulated with 
human recombinant IL-1β (5 ngml-1) 
(Calbiochem, UK) or PGE2 (0.01 μM or 1.0 
μM) (Sigma Aldrich, UK) and release of total 
collagen and COMP into tissue culture media 
quantified and compared to non-stimulated 
controls. After cutting (time 0), explants were 
incubated in serum deplete media and rested 
for 24 h to allow the tissue to adapt to the 
culture environment. Twenty-four hours after 
explant cutting, media were replaced and 
samples stimulated with pro-inflammatory 
mediators. The following inhibitors were 
added to the experimental system to identify 
inflammation-relevant release of COMP by 
intervention of the PGE2 synthesis pathways 
(including PGE2 synthesis via IL-1β): 1.0 μM 
Firocoxib (Merial, France), 20 μM Ilomastat 
(Calbiochem, UK), 400 ngml
-1
 recombinant 
equine IL-1Ra (R&D Systems, UK). Media 
were harvested and analysed at 48, 72 and 96 h 
(post-cutting) with complete media 
replacement at each interval.  
Viability of tendon explants in culture 
To demonstrate viability of tendon cells at the 
measured experimental time points, live-dead 
staining was performed with 4 μM ethidium 
bromide and 2 μM Calcein AM (Sigma-
Aldrich) in PBS containing 5.6 mM glucose, 
0.5 mM MgCl2 and 0.9 mM CaCl for 1 h in 
dark conditions prior to confocal microscopy  
(Leica Microsystems, Milton Keynes, UK). 
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Viability of explants cultured in serum deplete 
DMEM containing 5% penicillin and 
streptomycin were compared at 24 h and 120 h 
after cutting, with explants incubated in 2% 
sodium azide for 24 h as a negative control. 
ImageJ software (NIH version 1.42) was used 
to ascertain the proportion of live and dead 
cells.  
Sircol Collagen assay 
The Sircol collagen assay (Biocolor Ltd, UK) 
was used to quantify release of triple helical 
collagens into tissue culture media as per the 
manufacturer’s instructions. Briefly, 200 μL of 
culture media was assayed in triplicate in 96-
well micro titre plates and the final absorbance 
read at 555 nm (Sunrise micro plate reader, 
Tecan, Männedorf, Switzerland). The substrate 
background absorbance values were subtracted 
from absorbance readings and a standard curve 
generated using bovine type I collagen as 
specified by the assay manufacturer. Results 
were adjusted to represent collagen release per 
mg of explant wet weight measured at the 
termination of the experiment.  
COMP ELISA 
The COMP ELISA was an in-house assay that 
has been used successfully with equine 
samples, the methodology for which is 
described in detail elsewhere (31,32). COMP 
release was determined in samples of tissue 
culture media incubating tendon explants 
under differing experimental conditions. 
Results were expressed as μg/ml and 
subsequently adjusted to represent COMP 
release per mg of explant wet weight.  
SDS/PAGE and Western Blotting of 
COMP 
Western blotting of samples of culture media 
was used to compare the effects of pro-
inflammatory mediators on the release of 
COMP from tendon. Western blotting of 
undiluted media was performed under reduced 
and non-reduced conditions. Samples were 
reduced by addition of DTT to 0.1 M and 
heated to 95 °C for 5 mins prior to 
electrophoresis on 8-10% SDS/PAGE gels. 
Following electrophoresis, proteins were 
transferred for Western blotting (Bio-Rad, 
Hemel Hempstead, UK) onto PVDF 
membrane (GE Healthcare, Hertfordshire, 
UK). Membranes were blocked overnight in 
Tris buffered saline (0.02 M Tris-base, 0.02 M 
Tris HCl and 0.05 M NaCl) in 1% Triton 
(TBST buffer) containing 8% powdered 
skimmed milk (Marvel) and 2% bovine serum 
albumin (Sigma-Aldrich). After washing in 
TBST (three times for 10 mins each), 
membranes were incubated with the COMP 
primary antibody (25) in a buffer containing 
4% (w/v) milk and 1% (w/v) BSA in TBST at 
a 1:1000 dilution for 2 h. Membranes were 
washed three times as before and incubated 
with anti-rabbit IgG HRP-linked secondary 
antibody (Cell Signaling Technology
®
, MA, 
USA) in antibody buffer for 2 h at a 1:2000 
dilution. Antibody positive protein bands were 
visualised using enhanced chemiluminescence 
(ECL) reagent and film (GE Healthcare). 
Densitometric analysis of protein bands on 
non-reduced blots was performed using 
ImageJ software (NIH version 1.42) using 
sequential exposures of films to avoid 
saturation artefacts. 
Proteomic analyses using mass 
spectrometry 
Liquid chromatography mass spectrometry 
(LC-MS) using a Quadruple Time-of-Flight 
mass spectrometer (Q-TOF) (Q-TOF micro, 
Waters) were performed on samples of 
experimental media and extracts of normal and 
injured SDFTs. Multiple reaction monitoring 
(MRM) analyses were performed using 
another LC-MS system comprising of an Easy 
nano-LC
TM
 (Thermo Scientific) triple 
quadrupole instrument (TSQ Vantage
TM
, 
Thermo Scientific) on media samples from 
tendon explants in vitro for one experiment at 
72 h, enabling selective quantification of 
known peptides. The relative costs associated 
with the use of MS-MS precluded analyses of 
large numbers of samples. Proteomic analyses 
using MS-MS were performed to identify 
ECM proteins and neo-termini of COMP 
fragments released into media from stimulated 
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and control normal tendon explants in vitro, as 
COMP was the most abundant ECM protein 
released from tendon explants in culture. For 
these proteomic analyses, explants were cut 
(time 0) and rested for 48 h, as resting for 24 h 
in pilot studies suggested this was of 
insufficient duration due to a significant 
quantity of proteins and peptides released 
before baseline levels were reached at 48 h. At 
48 h, media were replaced and the tissue 
stimulated with pro-inflammatory mediators 
for a further 24 h. All media samples for 
proteomic analyses were analysed at the 72 h 
time point after explant cutting.  
Preparation of media samples for the Q-
TOF MS  
Care was taken to avoid contamination of 
samples with skin and hair keratins. 100 μL of 
media from each sample was reduced with 4 
mM DTT and agitated at 56 °C for 30 min. 
Samples were alkylated with 16 mM 
iodoacetamide (IAA) at room temperature in 
the dark for 1 h. Samples were digested with 
0.5µg trypsin gold (Promega, Madison, WI) 
overnight at 37 °C on a shaker for 16 h. 
Samples were dried in a Speedvac and 
suspended in 100 µl 0.2% formic acid whereof 
10 µl were purified and desalted using 
homemade reversed phase tips, 4 discs thick 
(47-mm Empore C18 extraction discs, 3M, 
Minneapolis, MN) as described before (44,45) 
and subsequently dried and re-dissolved in 20 
µl 0.2% formic acid before injection onto the 
Q-TOF MS. 
 
Preparation of media samples for the 
triple quadrupole MS 
Media samples (10µl trypsin digest, see above) 
were cleaned with reversed-phase C18 
columns according to the manufacturer’s 
instructions (SEM SS04V-SS18V), columns 
were purchased from the Nest Group (MA, 
USA). 
 
Preparation of tendon tissue extracts for 
QTOF MS analysis 
Proteomic analyses were also performed on 
tissue extracts from macroscopically normal, 
sub-acute (3-6 weeks post injury) and chronic 
injured (>3 months post injury) SDFTs to 
investigate the effect of injury on matrix 
protein composition. Samples of normal, sub-
acute and chronic injured SDFTs (n=3 of each) 
stored at -80 °C were finely diced and 15 
volumes of 4 M GdnHCl containing protease 
inhibitors (1:100 dilution of protease inhibitor 
cocktail III, Calbiochem) and 10 mM 
ethylenediaminetetraacetic acid (EDTA). 
Samples were rotated at room temperature for 
48 h and then centrifuged at 4° C for 15 mins 
at 13, 000 x g to recover the extract. 50 μL of 
extract was reduced in 10 mM DTT at 56 °C 
on a shaker for 30 min and alkylated at 40 mM 
IAA for 60 min at room temperature in the 
dark. Extracts were precipitated with ice-cold 
ethanol (9:1) for overnight at 4 °C before 
centrifugation (13,200 × g at 4 °C for 30 mins) 
followed by ethanol wash for 4 h at -20 °C to 
remove residual GdnHCl and other salts. 
Samples were dried in a SpeedVac and 
suspended in 100 μl of 0.1 M 
triethylammonium bicarbonate, pH 8.5, before 
trypsination with 1 μg of trypsin gold at 37 °C 
on a shaker for about 16 h. Samples were 
purified and concentrated using homemade 
reversed phase tips. 
MS-MS Data analyses of COMP peptides 
For Q-TOF LC-MS (Q-TOF micro, Waters) 
mass spectrometric raw data were processed 
using Protein Lynx 2.1 (Waters). Peptide and 
neo-termini searches were performed using the 
databases (SwissProt 56.9 and ENSEMBL) 
and MASCOT MS/MS Ions Search (version 
2.1). Due to the presence of collagens in 
tendon, hydroxylation of proline residues were 
allowed in database searches. MASCOT 
search parameters included: 
carbamidomethylation of cysteine as fixed 
modification, deamidation (Asn and Gln), and 
oxidation (Met and Pro) were considered as 
variable modifications. Other MASCOT 
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search parameters were: monoisotopic masses, 
±0.2Da peptide mass tolerance, ±0.2Da 
fragment mass tolerance, max miss cleavage 
of 2, ion score minimum 20, only highest 
ranked peptide matches, and taxonomy equus 
caballus. MRM data were analyzed using the 
Skyline 1.4 software (MacCoss Lab Software, 
University of Washington).  
Statistical analyses 
Statistical analyses were conducted using 
SPSS PASW Statistics 18 (SPSS Inc Illinois, 
USA). Linear mixed models were used to 
analyse COMP release to account for effects 
of horse, experimental condition and time. 
Analyses for release and percentage change in 
release relative to the respective controls are 
shown for COMP. p<0.05 was considered 
statistically significant.  
Ethics Statement 
Ethical approval for the collection of post 
mortem equine tendons from an abattoir or 
local equine veterinary referral hospital for this 
study was sought and approved from the 
Ethics and Welfare Committee at the Royal 
Veterinary College (URN 2011 1117). 
Results 
Tendon explant viability in vitro 
Confocal images illustrating explant viability 
are shown in Fig. 1. After culture for 24 h in 
serum deplete media, 90 ± 5% of cells within 
SDFT explants were viable. Explant viability 
was 60 ± 5% after 120 h in culture. The 
majority of cell death present was located 
along the periphery of the cut edges in a linear 
pattern along rows of tenocytes.  
Effects of IL-1β and PGE2 on the 
tendon ECM  
Minimal collagen degradation by IL-1β 
and PGE2 stimulation 
Soluble collagens released from tendon 
explants treated with IL-1β or PGE2 was 
minimal and ranged between 0.01-0.03 μg/mg 
of tissue in all samples between 24-96 h, but 
this was not significantly different from 
control cultures. 
Release of COMP after IL-1β and PGE2  
stimulation 
Mean COMP levels in media were 0.26 ± 0.1 
μg/mg in the first 24 h equilibration period in 
unstimulated cultures. This 24 h period was 
not included in statistical analyses. The 
cumulative release of COMP significantly 
increased in all samples with time between 48-
96 h (p=0.008) and was substantially increased 
by IL-1β (~10-fold increase) compared to 
control samples (Fig 2A). Although there was 
increased COMP release after stimulation with 
1.0 μM PGE2, this was not statistically 
significantly different compared to controls. 
COMP release was significantly reduced by 
addition of IL-1Ra (400 ngml
-1
) and Firocoxib 
(1.0 μM) (p<0.001 and p=0.004 respectively) 
but not by Ilomastat (Fig 2B).  
Analysis of ECM proteins in media by 
Western blotting  
Analysis of culture medium from the tendon 
explant experiments confirmed the release of 
COMP from the tendon ECM over the 120 h 
culture period (Fig. 3). COMP was released in 
a number of known multimeric forms (25), 
which could be identified in non-reducing 
conditions (Fig. 3A-NR) and migrated as a 
single monomeric form in reducing conditions 
(Fig. 3A-R).  The release of COMP from the 
tissue increased to a maximum at 48 h after 
explant cutting. Stimulation with 5 ngml
-1
 IL-
1β induced additional release of COMP as 
early as 15 h but was most marked after 48 h 
compared to controls (Fig. 3B R and NR) and 
included an approximately 100 kDa protein 
fragment not present in the control cultures 
under reduced conditions (Figs. 3 and 4). 
Fragments smaller than 100 kDa were 
observed with IL-1β after 15 h stimulation 
(Fig. 3). Qualitative assessment of western 
blots loaded with the same volume of media 
(Fig. 4) supported the increased release of both 
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monomeric (110 kDa) and fragmented COMP 
(~100 kDa) with 1.0 M PGE2, which was not 
significant by ELISA (Fig 2A). However 
fragments smaller than 100 kDa were only 
observed after stimulation at the higher PGE2 
dose (1.0 μM) and in contrast to IL-1β these 
fragments were present in relatively low 
abundance (Fig. 4). Combined addition of IL-
1β with low or high doses of PGE2 had no 
additional effect on COMP release.  
Proteomic analyses of culture media 
by mass spectrometry 
LC-MS and Q-TOF analyses 
Semi quantitative LC-MS analyses showed 
COMP to be the most abundant ECM protein 
released in all media samples from stimulated 
and non-stimulated explants, followed by 
thrombospondin-4, clusterin and fibronectin 
(Table 1). Stimulation with IL-1β (5ngml-1) 
induced a ~2-fold increase in COMP release 
compared to other experimental conditions.  
Consequently further analyses were focused 
on COMP and its related fragments. A list of 
neo-terminal peptides of COMP produced 
under different inflammatory stimuli is shown 
in Table 2. Five of the COMP neo-terminal 
peptides present in control samples were also 
common to samples stimulated with each pro-
inflammatory mediator (i.e. present in all 
samples). Addition of IL-1β (5ngml-1) 
generated a greater number of neo-terminal 
peptides of COMP compared to controls and 
stimulation with 1.0 μM PGE2. The neo-
terminal peptides generated from explants 
stimulated with 0.01 μM PGE2 were identical 
to those released from controls. Interestingly, 
combined stimulation of tendon explants with 
IL-1β and low dose (0.01μM) PGE2, generated 
a greater number of neo-terminal peptides in 
contrast to IL-1β with high dose (1.0μM) 
PGE2 (Table 2).  
Targeted mass spectrometry using MRM 
MRM analyses were performed on 
experimental media samples after 72 h in 
culture from one experiment.  Using this 
approach it was possible to perform relative 
quantifications of known peptides and neo-
terminal fragments of COMP between samples 
stimulated with pro-inflammatory mediators 
and non-stimulated controls. There was a 
general trend for IL-1β stimulated tendon 
explants to release higher quantities of 
peptides compared to non-stimulated controls 
(Fig. 5A-F). The greatest numbers of peptides 
were generated when explants were incubated 
with both IL-1β and low dose (0.01 μM) 
PGE2.  
Proteomic analyses of normal and 
injured tendon 
Analyses of normal and natural diseased flexor 
tendons identified differences in protein 
expression profiles for a large number of 
proteins as summarised in Fig. 6. Twenty one 
proteins were common to normal, sub-acute 
and chronic injured tendons, although a greater 
number of additional proteins were identified 
in injured samples, including albumin, 
Tenascin-C, fibronectin and Annexin’s A1, 
A2, A5. COMP was identified in sub-acute 
and chronic injured tendons but was not the 
most abundant ECM protein in contrast to 
normal samples. COMP neo-terminal 
fragments detected in extracts of normal, sub-
acute and chronic injured SDFTs are shown in 
Table 3. Four COMP neo-terminal fragments 
were identified in tissue extract samples of 
sub-acutely injured tendons and one in the 
chronic injury stage. Of these 5 COMP neo-
terminal fragments identified in natural injury, 
C.AVGWAGNGLLCGR.D and 
F.CFSQENIIWANLR.Y were identified in the 
in vitro model system after stimulation with 
IL-1β. Quantitative MRM analyses showed 
that levels of the COMP neo-N-terminal 
fragment CFSQENIIWANLR, common to 
natural injury and the in vitro model were 
elevated in media from IL-1β stimulated 
tendon explants compared to non-stimulated 
controls and PGE2 stimulated samples.  
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Discussion 
Stimulation of tendon explants with two pro-
inflammatory mediators did not induce 
significant collagen release between 24-96 h.  
Hence, tendon explants exhibit similar 
behaviour to cartilage with respect to the lack 
of collagens released during the early stages of 
culture (46,47). However it was not possible to 
maintain good cell viability in tendon explants 
beyond 5 days, which is why this time interval 
was selected as maximal for this study. The 
increased release of COMP with IL-1β 
supports a catabolic role of IL-1β in tendon 
similar to that reported for cartilage 
(28,39,40), which was further confirmed by 
the abrogating effects of IL-1Ra. Firocoxib but 
not Ilomastat inhibited IL-1β induced COMP 
release. Previous studies have shown that 
proteinases other than MMPs may be 
responsible for COMP degradation in vitro by 
aggrecanases such as ADAMTS-4 (28), which 
are not inhibited by Ilomastat, although the 
effects of aggrecanase inhibitors were not 
explored in the current study.  
Although we did not investigate the effects of 
strain on tendon, stress deprivation has been 
shown to induce IL-1 production (48) and 
stress deprivation may occur in injury, which 
may explain some of the neo-terminal peptides 
observed in diseased tendon. COMP was 
readily released from the matrix, which may 
be either the consequence of weaker 
interactions with matrix components compared 
to other matrix proteins, or that the released 
COMP is newly synthesised. However, the 
presence of cleaved forms of COMP in control 
samples would be more consistent with a 
proteolytic mediated release. Whilst cell death 
may have released intracellular proteases, it is 
unlikely that this was the major source of 
fragments because our control samples 
differentiated those fragments generated or 
substantially elevated following cytokine 
addition. IL-1β stimulation enhanced the 
release of cleaved forms of COMP and further 
degradation of monomeric COMP (<100 kDa, 
Fig. 3B). Neither the low nor high dose of 
PGE2 enhanced additional fragmentation 
patterns over control samples. However, MRM 
analyses showed trends for combined 
stimulation with IL-1β and PGE2 that 
produced differing effects depending on the 
concentration of PGE2. Stimulation with IL-1β 
and low dose PGE2 resulted in increased 
release of cleaved peptides of ECM proteins, 
whilst IL-1β and high dose PGE2 limited the 
number of neo-terminal cleavage sites. The 
synergy between low dose PGE2 and IL-1β on 
peptide release in this study is curious and 
could be explained by a number of hypotheses. 
First, the kinetics of prostaglandin (EP) 
receptor occupancy may be prolonged by the 
higher concentration of PGE2, leading to 
receptor desensitisation, which would dampen 
receptor effects. Second, the presence of 
higher levels of PGE2 may exert an auto-
regulatory feedback effect on IL-1 activity in 
order to modulate the inflammatory reaction 
(49). Third, the higher doses of PGE2 can 
activate resolution of inflammation in tendon 
fibroblasts via the production of specialised 
pro-resolving mediators such as lipoxins (50). 
This has been reported in an identical 
experimental system whereby addition of 1.0 
μM PGE2 to normal tendon explants induced 
maximal LXA4 release after 72 h in tissue 
culture (3). We have demonstrated combined 
stimulation of explants with IL-1β and the 
same concentrations of PGE2 similarly induced 
LXA4 release, with greater production with the 
higher dose of PGE2, suggesting that PGE2 
may exert anti-catabolic effects on tendon 
ECM (36).  
Comparative proteomic analysis of normal and 
naturally diseased tendons identified 
differences in protein / peptide profiles. The 
presence of Annexin A1 identified only in the 
sub-acute and chronic injury samples implicate 
both inflammatory and pro-apoptotic 
mechanisms are active (51), and continue into 
the later stages of tendon healing. COMP was 
also identified in samples of injured SDFT but 
it was not the most abundant protein, in 
contrast to normal tendons, suggesting a 
change in the tendon protein profile after 
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injury. Both injury phases had a similar 
number of proteins identified by proteomic 
analysis although the greater number of 
proteins unique to sub-acute disease suggests 
that a large change in the phenotype of tendon 
cells is a feature of early disease stages and 
this change to a large extent persists into 
chronic disease.  This failure of the protein 
profile to return to normal suggests that injury 
permanently changes the composition of 
tendon ECM, which may compromise both the 
mechanical properties of the tissue and its 
influence on the responses of tenocytes in 
maintaining homeostasis. This may be a 
contributing factor to the high risk of re-injury 
in horses due to the formation of a repair scar 
with inferior mechanical properties to normal 
tendons (23,52).  
MRM analyses showed that levels of the 
F.CFSQENIIWANLR.Y COMP peptide in 
sub-acute injury were also elevated after IL-1β 
stimulation of tendon explants. MRM analyses 
suggest that the relative abundance of the 
F.CFSQENIIWANLR.Y fragment is greater 
after stimulation with IL-1 β rather than PGE2. 
Furthermore, the C.AVGWAGNGLLCGR.D 
COMP fragment was only identified after 
stimulation with IL-1β and not PGE2 (low or 
high dose) and therefore the presence of these 
fragments in vivo provides supportive 
evidence that IL-1 is active in naturally 
occurring injury. 
The identification of novel COMP peptide 
cleavage sites common to both natural disease 
and an in vitro model of tendon inflammation 
provide a platform for the development of 
antibodies to identify stage of tendon injury 
and enzyme inhibitors for therapeutic 
intervention. The combination of these disease 
specific fragments may allow a multiplex 
marker platform to be developed for tendon 
injury. 
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Figure legends 
 
Figure 1 
Viability of tendon fibroblasts in explant culture. Confocal fluorescence micrographs of tendon 
sections treated with Calcein AM to denote cytoplasmic staining of live cells (green) and ethidium 
bromide for nuclear staining (red) of live and dead cells.  Explants after (A) 24 h and (B) 120 h.  Cell 
viability was 90 ± 5% after 24 h in culture and 60 ± 5% after 120 h. (C) Azide treated explant after 
24h was used as a negative control. All experiments were performed within the 120 h culture period. 
Scale bar = 20μm. 
Figure 2 
Release of COMP into media from SDFT explants in culture. Normal SDFT explants were derived 
from 3 horses aged between 9-13 years (mean 10 ± 2 years). Explants were rested for 24 h after 
cutting prior to media replacement and stimulation commencing. Media were harvested at 48, 72 and 
96 h with complete replacement at each time point. (A) Mean cumulative COMP release, showing 
significantly increased release with IL-1β stimulation alone and in combination with 20 μM Ilomastat. 
COMP release after stimulation with 1.0 μM PGE2 was similar to non-stimulated controls. (B) Mean 
percentage change in COMP release relative to the respective control.  Addition of either 400 ngml
-1
 
IL-1Ra or 1.0 μM Firocoxib significantly reduced IL-1β mediated COMP release. Error bars represent 
standard deviation. *p<0.05, **p<0.01, ***p<0.001. 
Figure 3  
COMP release into culture media from normal SDFT explants. Representative Western blots of media 
from experimental samples showing COMP release with time from control (A) and IL-1β stimulated 
tendon explants (B) under non-reduced (NR) and reduced (R) conditions. Densitometric analysis of 
protein bands is shown for non-reduced western blots. COMP release was enhanced by stimulation of 
explants with IL-1β compared to non-stimulated controls, with maximal release occurring at 48 h and 
the appearance of a number of distinct peptides <100 kDa.  In IL-1β stimulated explants, monomeric 
COMP appears as a doublet under reduced conditions from 15-120 h after explant cutting, which is 
better demonstrated in a lower exposure of the blot in a lower panel.  T= equine SDFT extract (total 
protein loaded 10μg) prepared in 4 M (GdnHCl) was used as a loading standard and as a positive 
control for COMP which is present mostly as a 550 kDa pentamer in the tissue. 
Figure 4 
Differential effects of IL-1β and PGE2 on COMP release.  Representative Western blot of media 
samples harvested at 4 h (A) and 48 h (B). Tendon extract = positive control (10 μg total protein); 
Control = media from unstimulated tendon at the same respective time point. COMP release and 
fragmentation were enhanced by stimulation with IL-1β at 48 h with lower molecular weight 
fragments present including the appearance of the 100 kDa peptide (doublet). Addition of PGE2 
resulted in the release of both intact and fragmented COMP (100 kDa) at 48 h.  Smaller fragments 
were detected with the higher dose of PGE2 but these were present in low abundance compared to 
stimulation with IL-1β.  
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Figure 5 
MRM analyses of COMP peptides released into media after 72 h in culture: (A) AVAEPGIQLK, (B) 
ELQETNAALQDVR, (C) IDVCPENAEVTLTDFR, (D) LVPNPGQEDADR, (E) SSTGPGEQLR 
and (F) COMP neo-terminal fragment CFSQENIIWANLR. Each sample was run on the MRM in 
triplicate and the mean values with standard deviation are shown for each experimental condition. 
MRM analyses were conducted on triplicate samples from one experiment and not biological 
replicates, hence statistical analyses were not performed. Peak normalised area represents the summed 
area of the ion peak transitions for each peptide measured. There was a trend for enhanced COMP 
peptide/neo-N-terminal fragment release with IL-1β compared to non-stimulated controls. For all 
peptides, maximal release occurred after stimulation with both IL-1β and 0.01 μM PGE2.  
 
Figure 6 
Venn representation of proteins identified from Q-TOF LC-MS. Samples of extracts of normal, sub-
acute and chronic injured equine SDFT samples (n=3 for each) were analysed for global protein 
composition, demonstrating differences in tendon ECM protein expression profiles with injury stage.  
While a similar number of proteins were identified in both sub-acute and chronic injury phases, it was 
in the sub-acute phase injury that the greatest numbers of unique proteins were present.  
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Tables 
Table 1 
Top ranking identified tendon ECM proteins (by protein score) released into media by pro-
inflammatory mediators.  Protein abundance was measured by semi-quantitative LC-MS and is 
indicated by the exponentially modified protein abundance index in parenthesis (emPAI). 
Rank of protein Control IL-1β (5 ngml-1) PGE2   (0.01µM) PGE2 (1.0 µM) 
1 COMP (3.44) COMP (6.41) COMP (3.84) COMP (3.08) 
2 Thrombospondin 
4 (1.35)  
Thrombospondin 
4 (1.7) 
Thrombospondin 
4 (1.28) 
Thrombospondin 
4 (0.92) 
3 Fibronectin (0.6) Clusterin (0.85) Clusterin (0.85) Clusterin (0.5) 
 
4 Clusterin (0.5) Fibronectin (0.51) 
 
Fibronectin (0.74) Fibronectin (0.49) 
5 Decorin (0.09) Interleukin-6 
(0.56) 
Collagen 3 (0.23) Decorin (0.3) 
6 Thrombospondin 
1 (0.06) 
Collagen 3 (0.17) 
 
Thrombospondin 
1 (0.06) 
Collagen 3 (0.29) 
7 CILP-1 (0.06) Thrombospondin 
1 (0.11) 
CILP-1 (0.06) Thrombospondin 
1 (0.08) 
8 Collagen 1 (0.06) Aggrecan (0.05) 
 
Aggrecan (0.03) Aggrecan (0.02) 
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Table 2 Summary of Q-TOF LC-MS analyses for neo-terminal peptides of COMP released into media from stimulated tendon explants. Numbers indicate 
the position of the peptide within the equine COMP protein sequence (NCBI accession AF325902). 
Control 
 
IL-1 
 
1.0 μM PGE2 0.01 μM PGE2 + IL-1 1.0 μM PGE2 + IL-1 
 
228 - 238 
C.PDGTPSPCHEK.A* 
37 - 48 
E.LQETNAALQDVR.E 
89 - 108    
Q.CAPGSCFPGVACTQTASGA
R.C 
 
37 - 48 
E.LQETNAALQDVR.E 
 
81 - 88 
R.VSVRPLAQ.C 
294 - 303 
V.PNSGQEDADR.D* 
88 - 108 
A.QCAPGSCFPGVACTQTASGAR.C 
 
 88 - 108    
A.QCAPGSCFPGVACTQTASG
AR.C 
 
89 - 108    
Q.CAPGSCFPGVACTQTASGAR.C 
 
642 - 649 
S.TGPGEQLR.N * 
89 - 108      
Q.CAPGSCFPGVACTQTASGAR.C 
 89 - 108    
Q.CAPGSCFPGVACTQTASGA
R.C 
 
724 - 736 
F.CFSQENIIWANLR.Y* 
 
203 - 222     
F.QCGPCQPGFVGDQASGCRPR.A 
 254 - 266 
C.AVGWAGNGLLCGR.D 
 
 
726 – 736 
F.SQENIIWANLR.Y * 
 
254 - 266    
C.AVGWAGNGLLCGR.D 
 725 – 736   
C.FSQENIIWANLR.Y 
 
 269 - 279 
T.DLDGFPDEKLR.C 
 
   
 320 - 330   V.PNEGDNCPLVR.N    
 600 - 613 
F.GYQDSSSFYVVMWK.Q 
 
   
*Denotes the neo-terminal peptide was present in all samples, including 0.01 μM PGE2 stimulated samples, which were the same as controls. Sequences shown with a dot 
represent the cleavage site and the residue following the dot represents the neo-terminus. IL-1 dose is 5 ngml-1 for all samples.  
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Table 3 
Summary of COMP peptides unique to natural SDFT injury. Numbers indicate the peptide position 
within the equine COMP protein sequence. 
1
Peptides common to sub-acute tendon injuries and IL-1β 
stimulated tendon explants. 
2
Levels of the F.CFSQENIIWANLR.Y peptide were increased in media 
from IL-1β stimulated tendon explants compared to controls. 
 
Normal SDFT Sub-acute SDFT injury Chronic SDFT injury 
228 - 238 
C.PDGTPSPCHEK.A 
 
254 - 266     
C.AVGWAGNGLLCGR.D
1
 
                   682 - 692 
R.WFLQHRPQVGY.I 
726 - 736 
F.SQENIIWANLR.Y 
652 - 663 
A.LWHTGDTASQVR.L
1
 
 
 653 - 663 
L.WHTGDTASQVR.L
1
 
 
 682 - 692      
R.WFLQHRPQVGY.I 
 
 
 
 724 - 736     
F.CFSQENIIWANLR.Y
2
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Figures 
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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